AAPS 2009 :Innovations-PSMA Inhibitor as a Homing Device

Article

A Joint Presentation of Pharmaceutical Technology and

Young Innovators of 2009: Interviews with AAPS Graduate Student Winners

PSMA Inhibitor as a Homing Device

Subscribe to RSS feed of this series


Sumith A. Kularatne
Purdue University

Category: BIOTECHNOLOGY


Prostate-Specific Membrane Antigen (PSMA)-Targeted Imaging, Diagnosis, and Therapy of Prostate Cancer using a PSMA Inhibitor as a Homing Device

View Poster Presentation

Part 1

Part 2

Part 3

Related Articles



Winning Presentations


Listen to the Interviews



AAPS President

Dr. Patrick P. DeLuca, president of AAPS, discusses the organization’s programs and commitment to student scientists.

Listen>>


Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Sun Pharma Agrees to Acquire Checkpoint Therapeutics

Patrick Lavery
March 12th 2025
Article

The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
March 12th 2025
Article

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Stäubli Robotics Previews World’s First Cleanroom Mobile Robot for INTERPHEX Display

Patrick Lavery
March 11th 2025
Article

Sterimove will make its North American debut at the April 1–3, 2025 event.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

Patrick Lavery
March 10th 2025
Article

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.